Latest From AngioDynamics Inc.
Cancer rates are rising worldwide and as diagnostic techniques continue to improve, new surgical ablation devices are becoming crucial weapons in the growing arsenal of cancer treatment tools. These devices allow doctors to burn away tumors with precision, speed and safety, without the side-effects that patients undergoing radical cancer therapy often experience. This article provides an overview of the cancer ablation market, highlights the key players working on these devices and discusses their potential applications. It also includes critical insights from a leading interventional urologist on the pros and cons of using these various technologies in treating prostate cancer.
Device-maker AngioDynamics has agreed to pay $12.5m to resolve allegations the company encouraged health-care providers to submit false claims for two of the company’s products.
UK-listed BTG PLC is on a route to a major future in interventional medicine, having built solid foundations in licensing and specialty pharma. CEO Louise Makin describes the deal- and decision-making rationale that has allowed a mid-cap player to set billion-dollar plus ambitions in interventional medicine, based on organic and M&A growth.
The US agency released two final guidance documents with tips on 510(k)s for electrosurgical devices targeting general tissue cutting, coagulation or sealing indications.
- Diagnostic Equipment & Supplies
- Radiofrequency Devices
Surgical Equipment & Devices
- Minimally or Less Invasive
- Radiopharmaceuticals, Contrast Agents
- Therapeutic Areas
- Renal System
- North America
- Parent & Subsidiaries
- AngioDynamics Inc.
- Senior Management
James Clemmer, Pres. & CEO
Michael Greiner, EVP, CFO
- Contact Info
Phone: (518) 795-1400
14 Plaza Dr.
Latham, NY 12110
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.